Greenwich LifeSciences, Inc.
GLSI · Pharmaceutical Preparations · 14.7M shares · +0%/yr ↑ dilution · EDGAR filings ↗
Net buyback after stock comp: $283K (gross $8M, SBC $7M)
Reference price $29.83 · est. market cap ~$438M — last insider purchase, 2026-01-13 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D40Clinical/early-stage biotech — breast-cancer-vaccine clinical micro-cap, thin liquidity.
Strengths
- Liquidity — current ratio 1.1 (15th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC, CITADEL ADVISORS LLC
- Insider buyingInsider buying — 3 open-market buy(s) by 1 insider(s) (~$225,408, last 6mo) Form 4 ↗
- Notable holderHeld by 3 notable fund(s): STATE STREET CORP, GOLDMAN SACHS GROUP INC, FMR LLC (as of 2026-03-31)
- Trial readout soonUpcoming trial readout ~2026-12 — PHASE3 · Breast Cancer
Key metrics
Return on equity
-5480.5%
Return on assets
-313.3%
Current ratio
1.1×
Tangible book value
$353K
Cash & investments
$6M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-01-13 | Patel Snehal | Buy | 1.8K | $29.83 |
| 2026-01-12 | Patel Snehal | Buy | 2.9K | $27.54 |
| 2025-12-31 | Patel Snehal | Buy | 4.3K | $21.36 |
| 2025-12-30 | Patel Snehal | Buy | 2.9K | $21.73 |
| 2025-12-18 | Patel Snehal | Buy | 4.1K | $12.62 |
| 2025-11-25 | Patel Snehal | Buy | 4.6K | $8.37 |
| 2025-11-07 | Patel Snehal | Buy | 11K | $8.43 |
| 2025-10-31 | Patel Snehal | Buy | 2.3K | $9.26 |
| 2025-04-25 | Patel Snehal | Buy | 3.6K | $9.88 |
| 2025-04-17 | Patel Snehal | Buy | 5.4K | $8.98 |
| 2025-04-07 | Patel Snehal | Buy | 3.6K | $9.10 |
| 2025-04-04 | Patel Snehal | Buy | 5.5K | $8.73 |
| 2025-01-10 | Patel Snehal | Buy | 2.5K | $12.51 |
| 2025-01-07 | Patel Snehal | Buy | 1.8K | $13.75 |
| 2025-01-06 | Patel Snehal | Buy | 1.1K | $13.31 |
| 2025-01-03 | Patel Snehal | Buy | 3.4K | $12.95 |
| 2025-01-02 | Patel Snehal | Buy | 2.0K | $11.97 |
| 2024-12-31 | Patel Snehal | Buy | 2.4K | $11.36 |
| 2024-12-30 | Patel Snehal | Buy | 3.2K | $11.12 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05232916 ↗ | Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects Breast Cancer | PHASE3 | Recruiting | 2026-12-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 10-Q | 2026-06-04 | 2026-03-31 | 0001493152-26-027150 ↗ |
| 10-K | 2026-06-01 | 2025-12-31 | 0001493152-26-026651 ↗ |
| 8-K | 2025-12-18 | 2025-12-18 | 0001493152-25-028361 ↗ |
| 10-Q | 2025-11-14 | 2025-09-30 | 0001493152-25-023539 ↗ |
| 10-Q | 2025-08-14 | 2025-06-30 | 0001641172-25-024066 ↗ |
| 8-K | 2025-07-24 | 2025-07-19 | 0001641172-25-020843 ↗ |
| 10-Q | 2025-05-20 | 2025-03-31 | 0001641172-25-011731 ↗ |
| 10-K | 2025-04-15 | 2024-12-31 | 0001641172-25-004819 ↗ |
| 8-K | 2024-12-19 | 2024-12-19 | 0001493152-24-050777 ↗ |
| 10-Q | 2024-11-14 | 2024-09-30 | 0001493152-24-045938 ↗ |
| 10-Q | 2024-08-14 | 2024-06-30 | 0001493152-24-032278 ↗ |
| 8-K | 2024-06-17 | 2024-06-13 | 0001493152-24-024035 ↗ |